ABIVAX Société Anonyme (NASDAQ:ABVX) Receives New Coverage from Analysts at Guggenheim

Guggenheim began coverage on shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in a research note published on Monday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $50.00 target price on the stock.

Separately, Morgan Stanley boosted their target price on shares of ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an equal weight rating in a report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $32.00.

ABIVAX Société Anonyme Stock Performance

NASDAQ ABVX opened at $15.52 on Monday. ABIVAX Société Anonyme has a 12 month low of $7.99 and a 12 month high of $17.02. The business has a 50 day simple moving average of $14.51.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several large investors have recently bought and sold shares of the business. Blackstone Inc. bought a new stake in shares of ABIVAX Société Anonyme in the 4th quarter worth about $25,345,000. Commodore Capital LP purchased a new position in ABIVAX Société Anonyme in the fourth quarter worth about $20,277,000. Great Point Partners LLC bought a new stake in ABIVAX Société Anonyme during the fourth quarter worth approximately $16,585,000. Franklin Resources Inc. purchased a new stake in ABIVAX Société Anonyme during the fourth quarter valued at approximately $13,630,000. Finally, Rosalind Advisors Inc. bought a new stake in shares of ABIVAX Société Anonyme in the 1st quarter valued at approximately $5,411,000. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.